BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update
16 juin 2021 08h00 HE
|
BeyondSpring, Inc.
- NDA Filed by U.S. Food and Drug Administration (FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of CIN. A PDUFA date of November 30, 2021 has been assigned by the FDA -...
BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021
11 juin 2021 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today...
BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting
10 juin 2021 07h00 HE
|
BeyondSpring, Inc.
- Data further supports plinabulin’s fast onset of action and CIN prevention benefit in week 1 following chemotherapy - Single agent plinabulin (day 1 dose as chemotherapy), had...
BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual Meeting
08 juin 2021 07h00 HE
|
BeyondSpring, Inc.
NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting
07 juin 2021 07h00 HE
|
BeyondSpring, Inc.
- Data demonstrate that combination of plinabulin and pegfilgrastim offers superior benefit for reducing the incidence and severity of febrile neutropenia (FN) and hospitalization, with better...
BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors
04 juin 2021 07h00 HE
|
BeyondSpring, Inc.
Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapyFirst patient who failed Keytruda and chemotherapy...
BeyondSpring Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)
01 juin 2021 07h00 HE
|
BeyondSpring, Inc.
- The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date for November 30, 2021 - Plinabulin and G-CSF combination has the potential to raise the standard of care in CIN...
BeyondSpring to Present at the Jefferies Virtual Healthcare Conference on June 3, 2021
26 mai 2021 16h05 HE
|
BeyondSpring, Inc.
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today...
BeyondSpring Presents Phase 1 Data on the Anti-Cancer Effect of Plinabulin in Combination with Checkpoint Inhibitors in SCLC at the American Society of Clinical Oncology (ASCO) Annual Meeting
24 mai 2021 07h30 HE
|
BeyondSpring, Inc.
- Data from U.S. Phase 1 dose escalation investigator-initiated trial demonstrated favorable safety and tolerability. - Plinabulin, in combination with nivolumab and ipilimumab, shows 46% objective...
BeyondSpring to Present at the Bank of America Securities 2021 Health Care Conference on May 13, 2021
10 mai 2021 08h18 HE
|
BeyondSpring, Inc.
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today...